Cue Biopharma, Inc. (CUE): Price and Financial Metrics


Cue Biopharma, Inc. (CUE): $3.95

0.04 (+1.02%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CUE POWR Grades

  • CUE scores best on the Sentiment dimension, with a Sentiment rank ahead of 68.02% of US stocks.
  • CUE's strongest trending metric is Stability; it's been moving up over the last 179 days.
  • CUE's current lowest rank is in the Momentum metric (where it is better than 4.51% of US stocks).

CUE Stock Summary

  • With a one year PEG ratio of 172.65, CUE BIOPHARMA INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 86.9% of US stocks.
  • CUE's price/sales ratio is 13.36; that's higher than the P/S ratio of 91.97% of US stocks.
  • With a year-over-year growth in debt of 439.83%, CUE BIOPHARMA INC's debt growth rate surpasses 95.99% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to CUE BIOPHARMA INC, a group of peers worth examining would be CARA, PRTA, ONCT, AEVA, and EXAI.
  • CUE's SEC filings can be seen here. And to visit CUE BIOPHARMA INC's official web site, go to www.cuebiopharma.com.

CUE Valuation Summary

  • CUE's price/sales ratio is 13.3; this is 565% higher than that of the median Healthcare stock.
  • CUE's price/sales ratio has moved NA NA over the prior 60 months.

Below are key valuation metrics over time for CUE.

Stock Date P/S P/B P/E EV/EBIT
CUE 2022-11-25 13.3 2.5 -2.7 -2.4
CUE 2022-11-23 13.3 2.5 -2.7 -2.4
CUE 2022-11-22 12.0 2.2 -2.4 -2.2
CUE 2022-11-21 11.9 2.2 -2.4 -2.1
CUE 2022-11-18 12.2 2.2 -2.4 -2.2
CUE 2022-11-17 12.6 2.3 -2.5 -2.3

CUE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CUE has a Quality Grade of D, ranking ahead of 17% of graded US stocks.
  • CUE's asset turnover comes in at 0.057 -- ranking 313th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows CUE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.057 1 -4.121
2021-03-31 0.038 1 -2.398
2020-12-31 0.034 1 -1.802
2020-09-30 0.044 1 -1.622
2020-06-30 0.058 1 -1.826
2020-03-31 0.073 1 -2.258

CUE Price Target

For more insight on analysts targets of CUE, see our CUE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $29.83 Average Broker Recommendation 1.2 (Strong Buy)

CUE Stock Price Chart Interactive Chart >

Price chart for CUE

CUE Price/Volume Stats

Current price $3.95 52-week high $12.79
Prev. close $3.91 52-week low $2.18
Day low $3.74 Volume 85,000
Day high $3.98 Avg. volume 349,744
50-day MA $3.01 Dividend yield N/A
200-day MA $3.61 Market Cap 139.76M

Cue Biopharma, Inc. (CUE) Company Bio


Cue Biopharma, Inc., a preclinical stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat various cancers and autoimmune disorders. Its lead drug candidate comprises CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to HPV-related cancers. The company’s biologics drug candidates also include CUE-100 series to improve various tumor specific T cells; and CUE-200 series to reinvigorate exhausted T cells. It also offers MOD costimulatory optimization and discovery platform and viraTope T cell epitope discovery platform to develop novel biologics for addressing new indications in oncology and autoimmune disorders. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was founded in 2014 and is based in Cambridge, Massachusetts.


CUE Latest News Stream


Event/Time News Detail
Loading, please wait...

CUE Latest Social Stream


Loading social stream, please wait...

View Full CUE Social Stream

Latest CUE News From Around the Web

Below are the latest news stories about CUE BIOPHARMA INC that investors may wish to consider to help them evaluate CUE as an investment opportunity.

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences

BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, announced today that it will take part in two fireside chats, the first at the Piper Sandler 34th Annual Healthcare Conference, to be held November 29-December 1 in New York, and the second at the JMP Securities Hematology & Oncology Sum

Yahoo | November 22, 2022

JMP Securities Reaffirms Their Buy Rating on Cue Biopharma (CUE)

JMP Securities analyst Reni Benjamin reiterated a Buy rating on Cue Biopharma (CUE - Research Report) today and set a price target of $15.00. The company's shares opened today at $3.41.According to TipRanks, Benjamin is an analyst with an average return of -10.3% and a 33.50% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Spectrum Pharmaceuticals, and Allogene Therapeutics.Currently, the analyst consensus on Cue Biopharma is a Strong Buy with an average price target of $10.25, representing a 200.59% upside. In a report released yesterday, Piper Sandler also initiated coverage with a Buy rating on the stock with a $7.00 price target.

Brian Anderson on TipRanks | November 21, 2022

Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE)

Public Ventures, LLC, a wholly owned subsidiary of MDB Capital Holdings, LLC, completed its first financing as a broker-dealer for Cue Biopharma, Inc. (NASDAQ:CUE).

Yahoo | November 17, 2022

Cue Biopharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

Cue Biopharma ( NASDAQ:CUE ) Third Quarter 2022 Results Key Financial Results Revenue: US$68.0k (down 97% from 3Q...

Yahoo | November 16, 2022

Cue Biopharma Reports Third Quarter 2022 Financial Results

BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patient’s body, reported today third quarter 2022 financial results. The Company will host a business update call in conjunction with its financial results press release on November 14, 2022. Recent Business Updates Announced a $30 million private inves

Yahoo | November 14, 2022

Read More 'CUE' Stories Here

CUE Price Returns

1-mo 25.00%
3-mo 27.83%
6-mo 3.67%
1-year -65.26%
3-year -68.63%
5-year N/A
YTD -65.08%
2021 -9.59%
2020 -21.20%
2019 237.77%
2018 N/A
2017 N/A

Continue Researching CUE

Here are a few links from around the web to help you further your research on Cue Biopharma Inc's stock as an investment opportunity:

Cue Biopharma Inc (CUE) Stock Price | Nasdaq
Cue Biopharma Inc (CUE) Stock Quote, History and News - Yahoo Finance
Cue Biopharma Inc (CUE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7677 seconds.